hormone receptor-positive breast cancer
hormone receptor-positive breast cancer
Explore linked clinical trials. Standard reference: MONDO:070007930 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy | hormone receptor-positive breast cancer | Not yet recruiting | Not applicable | 2026-10-07 | NCT07759947 | |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, invasive breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT04569747 | |
| Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | COVID-19, Coronaviridae Infections, Infections, Neoplasms by Site, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, lung disorder, neoplasm, pneumonia, respiratory system disorder, respiratory tract infectious disorder, skin disorder, triple-negative breast carcinoma, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2026-10-02 | NCT07856225 | |
| PRE-ISPY Phase I/II Oncology Platform Program | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast neoplasm, carcinoma, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, hormone receptor-positive breast cancer, intestinal disorder, malignant colon neoplasm, metastatic malignant neoplasm, neoplasm, rectal cancer, rectal disorder, rectal neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-09-30 | NCT05868226 | |
| SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Not yet recruiting | Not applicable | 2026-09-28 | NCT07844759 | |
| Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast Cancer | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, hormone receptor-positive breast cancer, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Not stated | 2026-09-22 | NCT07833501 | |
| Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-16 | NCT05165225 | |
| Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-09-15 | NCT07796880 | |
| Study of Screening Brain MRIs in Stage IV Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-09-15 | NCT05115474 | |
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, hormone receptor-positive breast cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 | 2026-09-01 | NCT03401385 | |
| PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-26 | NCT07222215 | |
| ETHAN - ET for Male BC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, male breast carcinoma, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-24 | NCT05501704 | |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2026-07-21 | NCT07716046 | |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-07-16 | NCT07708194 | |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | hormone receptor-positive breast cancer | Recruiting | Phase 2 | 2026-07-16 | NCT05467891 | |
| CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-07-13 | NCT07366112 | |
| ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-07-13 | NCT06970912 | |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-22 | NCT05573126 | |
| EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC) | hormone receptor-positive breast cancer | Recruiting | Not stated | 2026-06-12 | NCT07646171 | |
| VS-6766+Abema+Fulv in Met HR+/HER- BC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-04-30 | NCT05608252 | |
| Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Not stated | 2026-04-03 | NCT07264998 | |
| A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer | Hot Flashes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, hormone receptor-positive breast cancer | Not yet recruiting | Not applicable | 2026-03-19 | NCT07294339 | |
| Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-03-11 | NCT05524584 | |
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, hormone receptor-positive breast cancer | Recruiting | Phase 2 | 2026-01-21 | NCT06518837 | |
| Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Not stated | 2025-07-18 | NCT07073755 |